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M A J O R A R T I C L E
Injection Drug Use Facilitates Hepatitis C Virus
Infection of Peripheral Blood Mononuclear Cells
Massimo Resti, Chiara Azzari, Maria Moriondo, Letizia Betti, Idanna Sforzi, Elio Novembre, and Alberto Vierucci
Department of Pediatrics, University of Florence, and Pediatric Hospital A. Meyer, Florence, Italy
Infection of peripheral blood mononuclear cells (PBMCs) with hepatitis C virus (HCV) has been demonstrated
and has been found to play a role in relapse of HCV disease and vertical transmission of HCV. Injection drug
use is thought to impair function of the immune system and induce tolerance to viruses; therefore, HCV
infection of PBMCs could be more likely to occur in injection drug users (IDUs) with HCV infection. Of 108
women who tested negative for human immunodeficiency virus type 1 and positive for HCV RNA, 51 had a
history of injection drug use and 57 had no known risk factor for HCV infection. HCV infection was found,
by nested reverse-transcription polymerase chain reaction analysis, in the PBMCs of 33 IDUs and of 13 non-
IDUs ( ). No correlation was found between infection of the PBMCs and HCV genotype or virusPp .00003
load. Route of transmission and viral factors, as well as immunologic dysfunction, may play a role in viral
tropism.
Infection of peripheral blood mononuclear cells
(PBMCs) with hepatitis C virus (HCV) has been dem-
onstrated by several groups [1, 2]. The role of PBMC
infection with HCV is controversial, but lymphocytes
may act as an HCV reservoir and may play a key role
in the relapse of HCV disease after the discontinuation
of IFN therapy [3] or after liver transplantation [4]. We
recently demonstrated that the presence of HCV RNA
in maternal PBMCs is highly associated with transmis-
sion of HCV to the newborn [5]. It has also been shown
that maternal injection drug abuse, independent of other
risk factors, such as coinfection with HIV type 1 (HIV-
1), represents a preeminent risk factor in the vertical
transmission of HCV [6, 7].
The conditions that might facilitate entry of HCV
Received 2 November 2001; revised 28 February 2002; electronically published
1 July 2002.
Financial support: This study was supported in part by a grant from the Italian
Health Department (Rome), a grant from the Pediatric Hospital A. Meyer (Research
Department), and a grant from the University of Florence.
Reprints or correspondence: Dr. Chiara Azzari, Dept. of Pediatrics, Via Luca
Giordano 13, I-50132 Firenze, Italy (azzaric@unifi.it); or Dr. M. Resti, same address
(m.resti@meyer.it).
Clinical Infectious Diseases 2002; 35:236–9
 2002 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2002/3503-0003$15.00
into PBMCs are still unknown. It is possible that these
conditions may be associated with a particular route of
infection, dysfunction of the immune system, or re-
peated infection with different variants of HCV. All of
these conditions are present in injection drug users
(IDUs). Actually, modulation of immune system func-
tion by drug use, which can promote immune system
tolerance to viruses and superinfection, has been de-
scribed in IDUs [8, 9]. Therefore, the aim of the present
study was to evaluate the prevalence of HCV infection
of PBMCs in HCV-infected women with a history of
injection drug use.
PATIENTS AND METHODS
All women who were included in the study had gone
to different obstetric clinics in Florence, Italy, during
pregnancy to undergo a routine blood examination that
was part of a prospective study of mother-to-infant
transmission of HCV. All women were tested either at
the time of delivery or within 1 month after childbirth.
Fifty-one consecutively evaluated HIV-1–negative and
HCV RNA–positive women who had a history of in-
jection drug use were studied. Fifty-seven consecutively
evaluated women who were negative for HIV-1 and
Injection Drug Use and HCV Infection of PBMCs • CID 2002:35 (1 August) • 237
Table 1. Main virological features and alanine aminotransfer-
ase (ALT) patterns of women included in a study of injection drug
use and hepatitis C virus infection.
Finding
IDUs
(n p 51)
Non-IDUs
(n p 57)
Age, median years (range) 26 (22–35) 29 (23–38)
ALT levela
Normal 34 (66.7) 38 (66.7)
Fluctuating 14 (27.4) 17 (29.8)
Always elevated 3 (5.9) 2 (3.5)
Hepatitis C virus genotype
1 20 (39.2) 32 (56.2)
2 4 (7.8) 9 (15.8)
3 18 (35.3) 8 (14.0)
4 9 (17.7) 8 (14.0)
Virus load, 105 copies/mL
Median 4.10 4.90
Range 0.08–20.28 0.005–13.57
NOTE. Data are no. (%) of women, unless indicated otherwise. IDU,
injection drug user.
a ALT levels were obtained from medical histories and records.
positive for HCV RNA and who had no known risk factor for
HCV infection were included in the control group.
All women who had a history of injection drug use had
stopped injecting drugs before pregnancy. For ethical reasons,
liver biopsies were not performed in the present study. How-
ever, 8 women with a history of injection drug use and 7 women
without such a history had undergone liver biopsy in previous
years. Histological examination of liver biopsy specimens ob-
tained from these 15 women had shown evidence of minimal
or mild chronic hepatitis, with no difference noted between
women who had a history of injection drug use and those who
did not.
Four patients who were IDUs and 3 patients who were non-
IDUs had been treated with IFN 12 years previously. None of
them had responded to therapy.
History of injection drug use was determined through the
use of standardized questionnaires and face-to-face interviews.
After verbal consent was obtained from the women, infor-
mation on injection drug use was also obtained through a
review of records from medical and injection drug use services.
PBMCs were obtained from all mothers at the time of de-
livery or within 1 month after childbirth. PBMCs were isolated
from 10 mL of heparinized whole blood by centrifugation over
density gradient (Lymphoprep; Nycomed Pharma) and were
washed 3 times in 10 mL of PBS. Aliquots of paired samples
of plasma and 106 PBMCs were stored at70C until use. Total
RNA was extracted from 100 mL of plasma, 500 mL of liquid
from the final PBMC washing, and 106 unthawed PBMCs by
use of resin, chloroform, and isopropanol (RNA fast II; Mo-
lecular Systems). The presence of HCV RNA was detected by
reverse-transcription PCR, as described elsewhere [5]. To avoid
obtaining false-positive results caused by sample contamina-
tion, we strictly followed the preventive measures of Kwok
and Higuchi [10], and negative controls were included in all
experiments.
Quantitative analysis of RNA was done at the same time that
the PBMC investigation was performed; the Amplicor HCV
Monitor (Roche Diagnostic Systems) was used. Virus genotypes
were determined for all mothers by use of a line probe assay
(Innogenetics).
Data were processed by use of the SPSSX statistical package
(SSPS). RNA copy numbers were reported as median and range
values. Differences were evaluated by use of the nonparametric
Mann-Whitney U test. Differences in frequencies were evalu-
ated by use of the test or Fisher’s exact probabilities.2x
RESULTS
Age, main virological features, and patterns of alanine ami-
notransferase (ALT) levels for all study subjects are shown in
table 1. All women studied had uncomplicated pregnancies. All
IDUs were heroin users.
No difference in virus load was found between IDUs and
non-IDUs. The ALT levels observed also did not differ between
the 2 groups. HCV genotype 3 was found significantly more
frequently among IDUs ( ), but no difference in thePp .02
distribution of other HCV genotypes was found in a compar-
ison of the 2 groups.
HCV RNA was demonstrated in PBMCs obtained from 33
of 51 IDUs and from 13 of 57 control subjects ( ).Pp .00003
HCV RNA was never found in the fluid from the final PBMC
washing.
No differences were found between the ALT levels (table 2)
or serum virus loads (figure 1) of mothers whose lymphocytes
harbored the virus and those of mothers whose lymphocytes
did not harbor the virus (median virus load, 4.11  105 HCV
RNA copies/mL [range, 0.08–20.28 HCV RNA copies/mL] vs.
4.89  105 HCV RNA copies/mL [range, 0.005–12.73 HCV
RNA copies/mL] [ ]).Pp .62
Genotype 1 was the most frequently noted genotype of cells
infected with HCV. However, no difference in serum HCV
genotypes was found between women whose lymphocytes were
HCV-RNA positive and women whose lymphocytes were not
HCV-RNA positive (table 2).
DISCUSSION
Infection of PBMCs with HCV occurs significantly more fre-
quently in young women with a history of injection drug use
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Table 2. Alanine aminotransferase (ALT) levels, distribution of
hepatitis C virus (HCV) genotypes, and virus loads among women
with or without infection of peripheral blood mononuclear cells
(PBMCs) with HCV.
Finding
HCV
infection
of PBMCs
(n p 46)
No HCV
infection
of PBMCs
(n p 62) P
ALT level
Normal 30 (65.2) 42 (67.8)
Fluctuating 14 (30.4) 17 (27.4)
Always elevated 2 (4.4) 3 (4.8)
HCV genotype
1 23 (50.0) 29 (46.8) .89
2 4 (8.7) 9 (14.5) .53
3 9 (19.6) 17 (27.4) .47
4 10 (21.7) 7 (11.3) .34
Virus load, 105 copies/mL
Median 4.11 4.89
Range 0.08–20.28 0.005–12.73 .62
NOTE. Data are no. (%) of women, unless indicated otherwise.
Figure 1. Serum virus loads in women with infection of peripheral
blood mononuclear cells by hepatitis C virus (HCV; 1) and in women
without hepatitis C virus infection in peripheral blood mononuclear cells
(2). Horizontal lines denote median values.
than in a similar population without parenteral exposure to
injection drugs. Data from the present study also confirm pre-
vious observations that HCV genotype 3a is more frequently
found in IDUs [11, 12] and that PBMC infection with HCV
does not correlate with virus load or HCV genotype [5, 13].
In particular, even though a higher percentage of genotype 1
was found in infected cells, the rate reflects the distribution of
HCV genotypes in a population of Italian adults with HCV
infection. No difference in HCV genotypes was found between
women whose PBMCs were infected with HCV and women
whose lymphocytes were not infected with HCV.
Its lack of correlation with ALT levels suggests that PBMC
infection with HCV probably does not correlate with disease
activity. Histological examination would be helpful in clarifying
this aspect, but, for ethical reason, such examination was not
possible in this study. Actually, all of the women included in
the study were completely asymptomatic and had normal liver
function; the large majority also had ALT levels that were con-
sidered to be within the normal range.
The mechanism through which PBMC infection occurs in
IDUs needs to be investigated, and different hypothesis may
be suggested. Many different variants of HCV may be found
in a single HCV carrier [14]. Repeated superinfection with
different HCV variants probably is common in IDUs who share
needles with partners who inject drugs [15]. As demonstrated
elsewhere [16], different HCV variants have tropism for dif-
ferent cells, and it can be speculated that the presence of mul-
tiple variants makes it more likely that one of them can infect
PBMCs. The fact that there remained a high prevalence of
PBMC infection among women who had been IDUs but who
had stopped injecting drugs at least 1 year before participating
in the study is not surprising, because HCV may persist in
PBMCs for years.
Virus entry into PBMCs might also be facilitated by the
immune system dysfunction that is commonly found in IDUs.
Actually, immunologic modification among IDUs has been rec-
ognized for several years [8, 17]. Opioids significantly inhibit
production of IFN-a and IFN-b and can induce lymphocyte
apoptosis. Those effects are probably mediated through the
opioid receptor, because they can be reversed by the opiate
receptor antagonist naloxone. Moreover, specific lymphocyte
proliferative response against viral proteins is reduced by many
opioids [8]. Other reports show that opiates suppress cell-
mediated immunity, such as T cell–dependent antibody pro-
duction by B lymphocytes or delayed-type hypersensitivity, and
decrease natural killer cell activity [7]. Therefore, injection
drugs, by modulating the immune response [8, 9], may facilitate
immune tolerance to HCV and entry of the virus into the
PBMCs.
Other hypotheses should consider the route of infection.
Actually, women with no known risk of HCV infection might
have been infected through the mucosal route [18], and the
rate of infection of PBMCs might be different when the host
is infected through the mucosal, rather than the parenteral,
route. Moreover, the amount of inoculum injected is probably
larger in IDUs than in patients with no known risk of infection,
and the fact that a larger inoculum might facilitate infection
of PBMCs cannot be excluded. This is confirmed by prelimi-
nary data obtained by our group’s study of a small population
of pregnant women with posttransfusion HCV infection. In
that cohort, the rate of infection of PBMCs with HCV, even
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though slightly lower than the rate demonstrated among IDUs,
was higher than the rate noted among non-IDUs. The low
number of patients studied prevents definitive conclusions from
being drawn.
Infection of PBMCs with HCV has been reported by several
groups [1], but the role of PBMC infection with HCV is con-
troversial. It has been demonstrated that lymphocytes may act
as a reservoir for HCV and may play a key role in relapse of
HCV disease either after liver transplantation [4] or after the
discontinuation of IFN therapy [3].
Several studies have demonstrated that injection drug use
is an important risk factor for vertical transmission of HCV
from HIV-positive [19] or HIV-negative [6] mothers to their
infants. There is good evidence that the fetus is exposed to
maternal blood and that infected PBMCs may pass from
HCV-positive mothers to their offspring. Actually, maternal
PBMCs may be found in cord blood samples at a frequency
of 1 per 104–105 nucleated cells [20]. We recently demon-
strated that maternal infection of PBMCs is crucial in mother-
to-infant transmission of HCV and that the presence of HCV
RNA in maternal PBMCs is highly associated with transmis-
sion of HCV to the neonate [5].
In conclusion, the results of this study show the high prev-
alence of PBMC infection among IDUs and contribute to ex-
plaining why maternal history of injection drug use represents
an important risk factor in the vertical transmission of HCV
[6, 7, 19].
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